ZD 4927

Drug Profile

ZD 4927

Latest Information Update: 11 Dec 2001

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antithrombotics
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Deep vein thrombosis; Thrombosis

Most Recent Events

  • 11 Dec 2001 Discontinued-I for Deep vein thrombosis in United Kingdom (Unknown route)
  • 11 Dec 2001 Discontinued-I for Thrombosis in United Kingdom (Unknown route)
  • 13 Dec 1999 Phase-I clinical trials for Thrombosis in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top